HOOKIPA Pharma Inc. (HOOK) Covered Calls
HOOKIPA Pharma Inc. is a biopharmaceutical company that developed a proprietary arenavirus platform for immunotherapies. Following a strategic pivot in 2025 and 2026, the company sold its lead infectious disease programs to Gilead and its oncology assets to NeoTrail Therapeutics. The firm is currently focused on a planned liquidation and dissolution process, seeking to distribute remaining cash proceeds to shareholders.
You can sell covered calls on HOOKIPA Pharma Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for HOOK (prices last updated Wed 1:50 PM ET):
| HOOKIPA Pharma Inc. (HOOK) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.16 | +0.01 | 1.16 | 1.16 | 6K | - | 0.0 |
| Covered Calls For HOOKIPA Pharma Inc. (HOOK) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 2.5 | 0.00 | 1.16 | 0.0% | 0.0% | |
| Jun 18 | 2.5 | 0.00 | 1.16 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Asset Divestiture
HOOKIPA Pharma Inc. (OTC: HOOK) transitioned from a clinical-stage developer to an asset-holding company in 2026. After developing a unique viral-vector platform for T cell induction, the company monetized its entire clinical pipeline. Significant transactions included the 2025 sale of HBV and HIV programs to Gilead Sciences and the March 2026 sale of its HB-200 and HB-700 oncology programs to NeoTrail Therapeutics. Consequently, the firm no longer maintains active internal drug development programs.
Current Status and Liquidation
Following a shareholder-approved plan in late 2025, HOOKIPA voluntarily delisted from the NASDAQ and moved to the OTC markets. The company is currently executing a plan of liquidation and dissolution. Its primary objective in 2026 is managing the close-out of its corporate affairs and determining the final liquidating distributions (if any) to be paid to common shareholders. This process is expected to span several years as the company resolves remaining liabilities and potential milestone-based claims.
Publicly traded peers (sector benchmarks) include:
- Gilead Sciences, Inc.: The primary acquirer of HOOKIPA’s infectious disease platform and a key sector benchmark.
- BioNTech SE: A leader in next-generation immunotherapy platforms and viral vectors.
- Moderna, Inc.: A primary peer in the programmable vaccine and immunotherapy market.
Strategic Outlook
The strategic roadmap for HOOK is now limited to the orderly wind-down of the business. Management’s priority is maximizing the value of the "deferred" portions of their asset sales, which may include future royalties or milestone payments from NeoTrail and Gilead. Investors should note that as an OTC-listed company in liquidation, HOOK presents high risk and low liquidity, with its ultimate value dependent on the success of its divested programs in the hands of its partners.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | TLT covered calls | 1. | QS covered calls | |
| 2. | NVDA covered calls | 7. | HYG covered calls | 2. | NOK covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | NOW covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | TLRY covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | INTC covered calls | |
Want more examples? HOOD Covered Calls | HOPE Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
